Bridgeway Capital Management LLC Has $284,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Bridgeway Capital Management LLC reduced its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 72.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,106 shares of the company's stock after selling 135,003 shares during the period. Bridgeway Capital Management LLC owned approximately 0.09% of Voyager Therapeutics worth $284,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after buying an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management grew its holdings in Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after buying an additional 2,444 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth approximately $60,000. Virtu Financial LLC bought a new position in Voyager Therapeutics in the 4th quarter valued at $100,000. Finally, Legal & General Group Plc raised its position in shares of Voyager Therapeutics by 65.2% during the fourth quarter. Legal & General Group Plc now owns 19,245 shares of the company's stock worth $109,000 after acquiring an additional 7,597 shares during the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the transaction, the chief executive officer now directly owns 430,931 shares in the company, valued at approximately $1,478,093.33. This represents a 2.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.39% of the company's stock.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock traded up $0.02 during trading hours on Friday, hitting $3.30. The company had a trading volume of 365,716 shares, compared to its average volume of 443,313. The firm has a market cap of $182.61 million, a P/E ratio of 4.65 and a beta of 0.95. The company has a 50-day moving average price of $3.43 and a two-hundred day moving average price of $4.78. Voyager Therapeutics, Inc. has a 1 year low of $2.75 and a 1 year high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. As a group, equities research analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Wall Street Analyst Weigh In

VYGR has been the topic of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Voyager Therapeutics has an average rating of "Buy" and a consensus price target of $13.39.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.